Ownership and insider activity for GeoVax Labs, Inc. (GOVX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform.
Price
| Price | $0.41 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-17 | SPENCER JOHN N JR | A-Award | 6,000 | $7K |
| 2026-06-17 | Morgan Jayne | A-Award | 6,000 | $7K |
| 2026-06-17 | MCNALLY ROBERT T | A-Award | 6,000 | $7K |
| 2026-06-17 | Lemerond Nicole | A-Award | 6,000 | $7K |
| 2026-06-17 | Kollintzas Dean G | A-Award | 6,000 | $7K |
| 2026-06-17 | CHASE RANDAL D | A-Award | 6,000 | $7K |
| 2026-06-17 | Sharkey John W. | A-Award | 17,600 | $21K |
| 2026-06-17 | Reynolds Mark | A-Award | 17,600 | $21K |
| 2026-06-17 | NEWMAN MARK J | A-Award | 17,600 | $21K |
| 2026-06-17 | McKee Kelly T. Jr. | A-Award | 17,600 | $21K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $454030 | $312727 | $260000 | $283341 | $9.9M | $11.4M | $27.6M | $6.5M | $5.5M | $3.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $28074 | $59758 | $121814 | $68603 | $182663 | $49006 | 0 | 0 | $659409 | 0 |
| Inventory | 0 | 0 | -$121814 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $544379 | $448074 | $620000 | $447264 | $10.2M | $11.6M | $28.9M | $7.9M | $7.9M | $5.3M |
| Property, Plant & Equipment | $54828 | $31151 | $22000 | $10606 | $159000 | $156938 | $2.4M | $209689 | $149974 | $940270 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | $80000 | $70000 | $60000 | $50000 |
| Total Assets | $610217 | $490235 | $642000 | $468880 | $10.4M | $11.8M | $31.3M | $9.3M | $8.2M | $6.3M |
| Accounts Payable | $75607 | $77581 | $125859 | $152653 | $267702 | $2.1M | $1.7M | $2.8M | $1.8M | $790750 |
| Short-term Debt | 0 | 0 | $260420 | $12500 | $183326 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $369847 | $811292 | $1.6M | $2.0M | $810309 | $5.4M | $4.7M | $3.5M | $3.1M | $1.9M |
| Long-term Debt | 0 | 0 | $39580 | $27243 | $14738 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $369847 | $811292 | $1.7M | $2.0M | $825000 | $7.4M | $4.7M | $3.5M | $3.1M | $2.5M |
| Retained Earnings | -$35.7M | -$37.9M | -$40.5M | -$42.8M | -$45.8M | -$64.4M | -$78.4M | -$104.4M | -$129.4M | -$150.8M |
| Total Equity | $240370 | -$321057 | -$1.0M | -$1.6M | $9.6M | $4.4M | $26.6M | $5.8M | $5.0M | $3.8M |
| Total Debt | 0 | 0 | $300000 | $39743 | $198064 | 0 | 0 | 0 | 0 | $843170 |
| Net Debt | -$454030 | -$312727 | $40000 | -$243598 | -$9.7M | -$11.4M | -$27.6M | -$6.5M | -$5.5M | -$2.2M |
| Working Capital | $174532 | -$363218 | -$1.0M | -$1.6M | $9.4M | $6.2M | $24.2M | $4.4M | $4.8M | $3.4M |
Financial Health
| Debt / Equity | 0.18 |
| Current Ratio | 1.54 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -42.54 |
Profitability
| Return on Equity | -561.15% |
| Return on Invested Capital | -463.53% |
| Return on Assets | -338.46% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAP · ADTX · AIMD · ANL · APLM · BLRX · ICU
Explore sector: Healthcare · Biotechnology
More sections of GOVX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks